Article
Oncology
Zev A. Wainberg, Peter C. Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi, In -Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Haci Mehmet Turk, Alexandra Teixeira, Christophe Borg, Erika Hitre, Adrian A. Udrea, Giovanni Gerardo Cardellino, Raquel Guardeno Sanchez, Helen Collins, Siddhartha Mitra, Yingsi Yang, Daniel V. T. Catenacci, Keun-Wook Lee
Summary: This study investigated the efficacy and safety of bemarituzumab in combination with mFOLFOX6 for the treatment of HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinomas. Although there was no statistically significant improvement in progression-free survival, bemarituzumab showed promising clinical efficacy.
Article
Medicine, Research & Experimental
Daniel Xia, Klaudia Nowak, Alberto Jose Leon, Neil Winegarden, Ada Wong, Natalie Boruvka, Phedias Diamandis, Runjan Chetty, Trevor Pugh, Tong Zhang, Kenneth Aldape, Tracy Stockley, Stefano Serra
Summary: The goal of this study was to develop a methylation-based droplet digital PCR for separating two cancer classes without sensitive and specific immunohistochemical stains. The assay used independent primers and dependent probes to assess a differentially methylated CpG site and achieved high accuracy in classifying gastric/esophageal and pancreatic adenocarcinomas. This easy-to-interpret, rapid, and inexpensive method can be implemented in clinical laboratories for differential diagnosis.
LABORATORY INVESTIGATION
(2023)
Article
Oncology
Lucy X. Ma, Kirsty Taylor, Osvaldo Espin-Garcia, Reut Anconina, Chihiro Suzuki, Michael J. Allen, Marta Honorio, Yvonne Bach, Frances Allison, Eric X. Chen, Savtaj Brar, Carol J. Swallow, Jonathan Yeung, Gail E. Darling, Rebecca Wong, Sangeetha N. Kalimuthu, Raymond W. Jang, Patrick Veit-Haibach, Elena Elimova
Summary: In de novo metastatic GE adenocarcinoma patients, ECOG, baseline NRI, and change in NRI during treatment were significant prognostic factors for overall survival, while sarcopenia was not. The use of NRI at baseline and during treatment can provide valuable prognostic information.
Article
Oncology
Roberto Fiocca, Luca Mastracci, Marialuisa Lugaresi, Federica Grillo, Antonietta D'Errico, Deborah Malvi, Paola Spaggiari, Anna Tomezzoli, Luca Albarello, Ari Ristimaki, Luca Bottiglieri, Elena Bonora, Kausilia K. Krishnadath, Gian Domenico Raulli, Riccardo Rosati, Uberto Fumagalli Romario, Giovanni De Manzoni, Jari Rasanen, Sandro Mattioli, EACSGE Study Grp
Summary: The study reassessed nearly 300 EA/EGJAs and identified a two-tiered grading approach based on a cut off of 6% poorly differentiated components. Two morphologic risk groups (lower risk and higher risk) were identified, adding significant prognostic value to the stage. Accurate morphologic description is essential for a better understanding of prognosis, molecular events, and treatment response.
Review
Oncology
Massimiliano Salati, Francesco Caputo, Alessandro Bocconi, Sara Cerri, Cinzia Baldessari, Federico Piacentini, Massimo Dominici, Fabio Gelsomino
Summary: Gastric and gastro-esophageal junction adenocarcinoma (GEA) is a significant public health problem worldwide. Angiogenesis plays a crucial role in its initiation and progression. Despite numerous clinical trials evaluating anti-angiogenic agents in GEA, the results are controversial. Researchers are currently investigating the molecular landscape, combination therapies, and biomarker-selected approaches to fully realize the potential of angiogenesis blockade in GEA.
FRONTIERS IN ONCOLOGY
(2022)
Article
Surgery
Yun-Suhk Suh, Deukchae Na, Ju-Seog Lee, Jeesoo Chae, EuiHyun Kim, Giyong Jang, Jieun Lee, Jimin Min, Chan-Young Ock, Seong-Ho Kong, Joshy George, Chengsheng Zhang, Hyuk-Joon Lee, Jong-Il Kim, Seong-Jin Kim, Woo Ho Kim, Charles Lee, Han-Kwang Yang
Summary: This study investigated the molecular characteristics of AGEJ compared with EAC and gastric adenocarcinoma, revealing that AGEJ is a combination of EAC-like and GCFB-like groups with consistently different molecular characteristics. The EAC-like group showed a significantly better response to lapatinib, indicating potential effective targeting by dual inhibition of ERBB2 and EGFR.
Article
Gastroenterology & Hepatology
Mengyao Shi, Zunqi Hu, Kaiming Wu, Dejun Yang, Hongbing Fu, Juanjuan Zhang, Dong Li, Weimin Wang, Weijun Wang, Zhenxin Zhu
Summary: Pyloromyotomy can effectively prevent delayed gastric emptying after proximal gastrectomy for AEJ and reduce bile reflux compared to Heineke-Mikulicz pyloroplasty.
JOURNAL OF GASTROINTESTINAL SURGERY
(2022)
Review
Gastroenterology & Hepatology
Hirokatsu Hayashi, Akitaka Makiyama, Naoki Okumura, Itaru Yasufuku, Chiemi Saigo, Tamotsu Takeuchi, Tatsuhiko Miyazaki, Yoshihiro Tanaka, Nobuhisa Matsuhashi, Katsutoshi Murase, Takao Takahashi, Manabu Futamura, Kazuhiro Yoshida
Summary: We present a case of postoperative recurrence of gastric carcinosarcoma under long-term tumor control with pazopanib. This case suggests that pazopanib may be effective in treating gastric carcinosarcoma.
BMC GASTROENTEROLOGY
(2022)
Article
Multidisciplinary Sciences
Thorben Schrumpf, Hans-Michael Behrens, Jochen Haag, Sandra Krueger, Christoph Roecken
Summary: The expression and tumor biological significance of FGFR2 in gastric cancer were independently validated in a non-Asian patient cohort. While FGFR2 expression did not correlate with overall patient survival, a negative correlation was found in diffuse-type gastric cancer, which was associated with lower tumor grade and intestinal phenotype.
Article
Oncology
Ilya Tsimafeyeu, Galina Statsenko, Liubov Vladimirova, Natalia Besova, Elena Artamonova, Grigory Raskin, Ivan Rykov, Anastasia Mochalova, Igor Utyashev, Svetlana Gorbacheva, Vasily Kazey, Evgenia Gavrilova, Nadezhda Dragun, Vladimir Moiseyenko, Sergei Tjulandin
Summary: Alofanib has shown acceptable tolerability and preliminary signs of clinical activity in patients with advanced gastric cancer. The study suggests that Alofanib may be a potential treatment option for late-line metastatic gastric cancer.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Manish A. Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C. Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L. Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M. Brooks, Bo Xu, Wei Li, Chiang J. Li, Laura Borodyansky, Eric Van Cutsem
Summary: Adding napabucasin to paclitaxel did not improve survival in patients with second-line advanced gastric or gastroesophageal junction adenocarcinoma. The safety profile of napabucasin was driven by manageable gastrointestinal events, with grade >= 3 diarrhea occurring at a higher frequency with napabucasin plus paclitaxel versus placebo plus paclitaxel.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Xue-Ke Zhao, Pengwei Xing, Xin Song, Miao Zhao, Linxuan Zhao, Yonglong Dang, Ling-Ling Lei, Rui-Hua Xu, Wen-Li Han, Pan-Pan Wang, Miao-Miao Yang, Jing-Feng Hu, Kan Zhong, Fu-You Zhou, Xue-Na Han, Chao-Long Meng, Jia-Jia Ji, Xingqi Chen, Li-Dong Wang
Summary: Frequent focal amplifications and ecDNAs were identified in Chinese GCA patients, with associations to chromothripsis process and dietary habits. The presence of oncogene focal amplifications in GCA patients showed diverse correlations with prognosis, highlighting ERBB2 focal amplifications as a potential prognostic marker in this population.
NATURE COMMUNICATIONS
(2021)
Review
Oncology
Yuki Hirata, Ayesha Noorani, Shumei Song, Linghua Wang, Jaffer A. Ajani
Summary: Gastric adenocarcinoma remains a challenging disease to diagnose and treat, with low cure rates, especially in Western countries. This is due to the impracticality of early diagnosis, regional variations in therapeutic approaches, and the heterogeneity of gastric cancer cells and their microenvironment. Targeted interventions based on molecular subsets of gastric adenocarcinomas identified by genomic and/or multi-omics analyses show promise for improved outcomes. Future strategies involving vaccines, novel antibody technologies, and agents targeting the tumor microenvironment and immune checkpoints, supported by improved diagnostic assays, hold potential for advancements in gastric cancer management.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Hiroaki Ito, Naoyuki Uragami, Tomokazu Miyazaki, Yuto Shimamura, Haruo Ikeda, Yohei Nishikawa, Manabu Onimaru, Kai Matsuo, Masayuki Isozaki, William Yang, Kenji Issha, Satoshi Kimura, Machiko Kawamura, Noboru Yokoyama, Miki Kushima, Haruhiro Inoue
Summary: This study proposes a method using Raman spectroscopy (RS) to detect cancer in unstained formalin-fixed specimens of the esophagus and stomach. The Raman-scattered light spectrum in these specimens changes due to histological differences in the tissue. By analyzing specific Raman shifts, an algorithm has been developed to identify esophageal squamous cell carcinoma (SCC) and gastric adenocarcinoma (AC) with accuracy comparable to histopathological diagnoses.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Multidisciplinary Sciences
Richard Shore, Jingru Yu, Weimin Ye, Jesper Lagergren, Martin Rutegard, Olof Akre, Par Stattin, Mats Lindblad
Summary: This study found that androgen deprivation therapy reduces the risk of non-cardia gastric adenocarcinoma, but does not decrease the risk of esophageal adenocarcinoma, cardia gastric adenocarcinoma, or esophageal squamous-cell carcinoma.
SCIENTIFIC REPORTS
(2021)
